Cantor Fitzgerald Reduces Earnings Estimates for Verastem

Verastem, Inc. (NASDAQ:VSTM) – Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Verastem in a note issued to investors on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the biopharmaceutical company will earn ($3.57) per share for the year, down from their previous estimate of ($3.24). The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem’s FY2026 earnings at ($3.69) EPS.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.24).

Several other brokerages have also issued reports on VSTM. Guggenheim increased their price target on shares of Verastem from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, March 24th. Mizuho decreased their price target on shares of Verastem from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, April 9th. HC Wainwright increased their price target on shares of Verastem from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Wall Street Zen lowered shares of Verastem from a “hold” rating to a “sell” rating in a research note on Friday, April 18th. Finally, Royal Bank Of Canada upgraded shares of Verastem from an “outperform” rating to a “moderate buy” rating and decreased their price target for the stock from $16.00 to $12.00 in a research note on Wednesday. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat.com, Verastem currently has an average rating of “Moderate Buy” and a consensus price target of $13.38.

Verastem Stock Down 0.2%

Shares of Verastem stock opened at $4.15 on Thursday. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.50 and a quick ratio of 3.50. The company has a 50-day moving average of $6.61 and a 200 day moving average of $5.98. The firm has a market cap of $228.04 million, a price-to-earnings ratio of -1.30 and a beta of 0.85. Verastem has a 1 year low of $2.10 and a 1 year high of $9.10.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 17,808 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $5.13, for a total transaction of $91,355.04. Following the sale, the chief executive officer now owns 443,839 shares of the company’s stock, valued at $2,276,894.07. This trade represents a 3.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Daniel Calkins sold 11,143 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.13, for a total transaction of $90,592.59. Following the sale, the chief financial officer now directly owns 114,055 shares in the company, valued at approximately $927,267.15. The trade was a 8.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 93,796 shares of company stock valued at $693,033. 2.10% of the stock is owned by insiders.

Institutional Trading of Verastem

A number of institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Verastem by 51.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,698 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Verastem by 18.4% during the 4th quarter. Invesco Ltd. now owns 14,680 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 2,281 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Verastem by 3.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 117,784 shares of the biopharmaceutical company’s stock valued at $710,000 after acquiring an additional 4,183 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Verastem by 31.2% during the 4th quarter. Jane Street Group LLC now owns 19,932 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 4,740 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Verastem by 10.3% during the 4th quarter. Barclays PLC now owns 61,445 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 5,737 shares during the last quarter. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.